Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Sells $34,630.54 in Stock

Trevi Therapeutics, Inc. (NASDAQ:TRVI) CEO Jennifer L. Good sold 5,263 shares of the company’s stock in a transaction that occurred on Friday, March 21st. The stock was sold at an average price of $6.58, for a total transaction of $34,630.54. Following the sale, the chief executive officer now directly owns 213,313 shares of the company’s stock, valued at approximately $1,403,599.54. This trade represents a 2.41 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Trevi Therapeutics Stock Performance

Shares of NASDAQ:TRVI traded up $0.21 during midday trading on Tuesday, hitting $6.61. 1,053,002 shares of the stock were exchanged, compared to its average volume of 994,539. The business’s 50-day moving average price is $4.65 and its 200 day moving average price is $3.78. Trevi Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $7.39. The stock has a market capitalization of $639.07 million, a price-to-earnings ratio of -15.02 and a beta of 0.90.

Trevi Therapeutics (NASDAQ:TRVI) last posted its earnings results on Tuesday, March 18th. The company reported ($0.11) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.12) by $0.01. As a group, sell-side analysts expect that Trevi Therapeutics, Inc. will post -0.49 EPS for the current year.

Analysts Set New Price Targets

TRVI has been the subject of several recent analyst reports. HC Wainwright restated a “buy” rating and set a $12.50 target price on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Raymond James upgraded Trevi Therapeutics from an “outperform” rating to a “strong-buy” rating and upped their price objective for the stock from $9.00 to $29.00 in a research report on Monday, March 10th. D. Boral Capital reiterated a “buy” rating and issued a $21.00 target price on shares of Trevi Therapeutics in a research report on Wednesday, March 19th. Needham & Company LLC lowered their target price on Trevi Therapeutics from $25.00 to $24.00 and set a “buy” rating for the company in a research note on Wednesday, March 19th. Finally, B. Riley restated a “buy” rating and issued a $20.00 price target (up from $11.00) on shares of Trevi Therapeutics in a research note on Wednesday, March 19th. Seven investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $17.56.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Summit Investment Advisors Inc. grew its position in shares of Trevi Therapeutics by 84.2% in the 4th quarter. Summit Investment Advisors Inc. now owns 6,332 shares of the company’s stock valued at $26,000 after buying an additional 2,894 shares during the last quarter. BNP Paribas Financial Markets lifted its stake in shares of Trevi Therapeutics by 130.9% in the third quarter. BNP Paribas Financial Markets now owns 11,930 shares of the company’s stock worth $40,000 after acquiring an additional 6,764 shares during the period. Raymond James Financial Inc. bought a new stake in Trevi Therapeutics in the fourth quarter valued at approximately $49,000. Squarepoint Ops LLC acquired a new stake in Trevi Therapeutics during the 4th quarter valued at approximately $58,000. Finally, Intech Investment Management LLC bought a new position in Trevi Therapeutics during the 3rd quarter worth approximately $63,000. 95.76% of the stock is owned by institutional investors.

About Trevi Therapeutics

Trevi Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapy Haduvio for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC) conditions targeting the central and peripheral nervous systems.